Pure Global
NCT05480501

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Beijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Leukemia
Drug/Device/Intervention
IM19 CAR-T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Location
Shenyang, China
Timeline & enrollment
Phase
Phase 1
Start date
Jul 11, 2022
End date
Oct 01, 2024
Enrollment
9 participants
Primary outcome

Incidence of adverse events (AEs),Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow )

Summary

This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell
 Acute Lymphoblastic Leukemia.

ICD-10 classifications
Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05480501
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05480501 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. and is currently Recruiting. The study focuses on Leukemia. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.